Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 39

1.

The rise and fall of Dimebon.

Bezprozvanny I.

Drug News Perspect. 2010 Oct;23(8):518-23. doi: 10.1358/dnp.2010.23.8.1500435.

2.

Latrepirdine, a potential novel treatment for Alzheimer's disease and Huntington's chorea.

Sabbagh MN, Shill HA.

Curr Opin Investig Drugs. 2010 Jan;11(1):80-91. Review.

3.

ACS chemical neuroscience molecule spotlight on dimebon.

Hopkins CR.

ACS Chem Neurosci. 2010 Sep 15;1(9):587-8. doi: 10.1021/cn1000588. Review.

4.

Latrepirdine: molecular mechanisms underlying potential therapeutic roles in Alzheimer's and other neurodegenerative diseases.

Bharadwaj PR, Bates KA, Porter T, Teimouri E, Perry G, Steele JW, Gandy S, Groth D, Martins RN, Verdile G.

Transl Psychiatry. 2013 Dec 3;3:e332. doi: 10.1038/tp.2013.97. Review.

5.

Dimebon as a potential therapy for Alzheimer's disease.

Doody RS.

CNS Spectr. 2009 Aug;14(8 Suppl 7):14-6; discussion 16-8. Review.

PMID:
19890242
6.

Galantamine for Alzheimer's disease.

Olin J, Schneider L.

Cochrane Database Syst Rev. 2001;(4):CD001747. Review. Update in: Cochrane Database Syst Rev. 2002;(3):CD001747.

PMID:
11687119
7.

Galantamine for Alzheimer's disease.

Olin J, Schneider L.

Cochrane Database Syst Rev. 2002;(3):CD001747. Review. Update in: Cochrane Database Syst Rev. 2004;(4):CD001747.

PMID:
12137632
8.

Selegiline for Alzheimer's disease.

Birks J, Flicker L.

Cochrane Database Syst Rev. 2003;(1):CD000442. Review.

PMID:
12535396
10.

Mitochondrial dysfunction--a pharmacological target in Alzheimer's disease.

Eckert GP, Renner K, Eckert SH, Eckmann J, Hagl S, Abdel-Kader RM, Kurz C, Leuner K, Muller WE.

Mol Neurobiol. 2012 Aug;46(1):136-50. doi: 10.1007/s12035-012-8271-z. Epub 2012 May 3. Review.

PMID:
22552779
11.

Dimebolin in dementia.

Sachdeva D, Burns A.

CNS Neurosci Ther. 2011 Jun;17(3):199-205. doi: 10.1111/j.1755-5949.2010.00156.x. Epub 2010 Jun 11. Review.

PMID:
20553307
12.

[Therapy of Alzheimer disease].

Kovács T.

Neuropsychopharmacol Hung. 2009 Mar;11(1):27-33. Review. Hungarian.

13.

Nimodipine for primary degenerative, mixed and vascular dementia.

López-Arrieta JM, Birks J.

Cochrane Database Syst Rev. 2002;(3):CD000147. Review.

PMID:
12137606
14.

Galantamine for Alzheimer's disease.

Olin J, Schneider L.

Cochrane Database Syst Rev. 2001;(1):CD001747. Review. Update in: Cochrane Database Syst Rev. 2001;(4):CD001747.

PMID:
11279727
15.
16.

Physostigmine for Alzheimer's disease.

Coelho F, Birks J.

Cochrane Database Syst Rev. 2001;(2):CD001499. Review.

PMID:
11405996
17.

Galantamine for Alzheimer's disease and mild cognitive impairment.

Loy C, Schneider L.

Cochrane Database Syst Rev. 2006 Jan 25;(1):CD001747. Review.

PMID:
16437436
18.

Role of serotonin in Alzheimer's disease: a new therapeutic target?

Geldenhuys WJ, Van der Schyf CJ.

CNS Drugs. 2011 Sep 1;25(9):765-81. doi: 10.2165/11590190-000000000-00000. Review.

PMID:
21870888
19.

Serotonin 5-HT6 receptor antagonists for the treatment of Alzheimer's disease.

Geldenhuys WJ, Van der Schyf CJ.

Curr Top Med Chem. 2008;8(12):1035-48. Review.

PMID:
18691131
20.

Metrifonate for Alzheimer's disease.

López-Arrieta JM, Schneider L.

Cochrane Database Syst Rev. 2006 Apr 19;(2):CD003155. Review.

PMID:
16625573
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk